You have no items in your shopping cart.
MAPS is the leading non-profit on the forefront of the legalization of psychedelic and entheogenic medicines through rigorous scientific research.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been working for 29 years to develop psychedelics and marijuana into prescription medicines, and to educate the public about their risks and benefits. MAPS has completed a Phase 2 FDA-approved study of MDMA-assisted psychotherapy for the treatment of PTSD. This study found that 83% of the treatment resistant subjects no longer had PTSD, and a long term follow up study found the results lasted at least 3.5 years after treatment.
Based on this early success, MAPS launched four new studies – based in the US in South Carolina and Colorado, and in Canada and Israel. These four studies will be complete within a year and, with FDA approval, within one-and-a-half years MAPS will begin its Phase 3 clinical research testing hundreds of subjects.
The goal is to make MDMA into a prescription medicine by 2021. In addition, MAPS is sponsoring a study of MDMA-assisted therapy to treat social anxiety in adults on the autism spectrum, and to treat extreme anxiety for those with life-threatening illness. Other studies include medical marijuana for treating PTSD in veterans, and observational studies of ayahuasca and ibogaine.
To educate the public, MAPS publishes a Bulletin, publishes and distributes books, maintains a website and psychedelic bibliography, hosts events and conferences, and supports a vigorous public relations effort to help change the way people think about psychedelics. To bring therapy to those in need now, MAPS sponsors the Zendo Harm Reduction Project, which offers services to festival-goers having challenging psychedelic experiences. Since psychedelics are off patent, there is no economic incentive to do this research. MAPS work, therefore, is funded by donations from visionary individuals who see these substance's potential.